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Available online 23 December 2010Staphylococcus aureus causes a variety of infections. Knowledge about the physiological role of
most S. aureus antigens in colonization and infection is only limited. This can be studied by
measuring antigen-speciﬁc antibody responses. In this study, we optimized the multiplex
microsphere bead-based ﬂow cytometry technique for mouse serum samples. We analysed
immunoglobulin G (IgG) levels directed against 26 S. aureus proteins in a single small-volume
mouse serum sample. We assessed possible cross reactivity. Furthermore, we analysed serum
samples from mice with different types of S. aureus infections caused by different S. aureus
strains. The results show that cross reactivity between proteins on microspheres and serum
antibodies towards other proteins was limited. We found that lung-infected mice had a higher
and broader IgG response than skin-infected mice. Clearly, the site of infection inﬂuences the
IgG proﬁle. Next, we compared sera frommice with intravenously-induced bacteraemia caused
by different S. aureus strains. We showed different IgG responses depending on the causing S.
aureus strain. It is concluded that the bead-based multiplex S. aureus antibody assay can be
successfully applied to determine the immunogenicity of different S. aureus proteins in relation
to the site of infection and the S. aureus strain causing the infection.
© 2010 Elsevier B.V. Open access under the Elsevier OA license.Keywords:
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Luminex1. Introduction
Staphylococcus aureus (S. aureus) causes a diverse arsenal
of infections, ranging from superﬁcial skin infections (fur-
uncles and impetigo) to invasive infections such as abscesses,
pneumonia, endocarditis, and bacteraemia (Lowy, 1998).
Little is known about the precise physiological role of many if
not most S. aureus antigens that are important in colonization
and infection. For some infections, some or at least one of the
S. aureus antigens important during infection are known. Foral Microbiology and
vendijkwal 230, 3015
fax: +31 107033875
an den Berg).
lsevier OA license..example, superantigens such as TSST-1 are predominant in
Toxic Shock Syndrome (Fraser and Proft, 2008); staphylo-
coccal enterotoxins are known to cause food poisoning (Le
Loir et al., 2003); and Panton Valentine Leukocidin is involved
in necrotizing pneumonia (Brown et al., 2009b).
Immunogenicity of antigens in these processes can be
studied by assessing the antigen-speciﬁc antibody responses
elicited. It is known that levels of antibodies to toxic shock
syndrome toxin 1 (TSST-1), staphylococcal enterotoxin A
(SEA), and clumping factors A and B (ClfA and ClfB) are
signiﬁcantly higher in persistent carriers of S. aureus than in
noncarriers (Verkaik et al., 2009a). Colonized children have
higher IgG levels against chemotaxis inhibitory protein of S.
aureus (CHIPS), extracellular ﬁbrinogen-binding protein (Efb),
and iron-responsive surface determinant H (IsdH), and higher
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(IsdA), and IsdH than non-colonized children in both the ﬁrst
and second years of life (Verkaik et al., 2009b). Although for
instance the course of the humoral immune response in
S. aureus bacteraemia patients as well as in pediatric patients
infected with community-associated S. aureus has been
investigated, the importance and therapeutic effect of antibody
induction in many other diseases remain enigmatic (Brown
et al., 2009a; Verkaik et al., 2010a). While clinical studies
remain the most informative in this respect, animal models of
S. aureus infectionenable investigation of antibody responses to
speciﬁc S. aureus antigens under similar conditions of S. aureus
colonization and infection as are encountered by humans. In
this way animal studies may provide insight into the potential
role of S. aureus antigens in the important processes of
colonization and infection. Experimental animal models of
different S. aureus infectionshave beendeveloped, andmice are
frequently used as models.
For quantiﬁcation of circulating antibody levels, conven-
tional immunological techniques such as the Enzyme-Linked
ImmunoSorbent Assay (ELISA) can be applied. This technique
is time- and serum-consuming, and antibodies against only
one antigen can be measured in one separate ELISA. To assess
levels of antibodies directed against a broad range of antigens,
multiple mice need to be bled to yield enough serum and this
may confound observations due to inter-experiment varia-
tions. The microsphere bead-based ﬂow cytometry technique
(xMap, Luminex Corporation, Austin, TX, USA) permits the
simultaneous analysis of antibodies for up to 100 different
antigens from a single, small-volume serum sample (Fulton et
al., 1997). To our knowledge, this technique has as yet only
been used for measuring antibodies against S. aureus proteins
in human serum samples (Martins et al., 2006; Verkaik et al.,
2009a, 2010b). In the present study, we optimized the
Luminex technology to quantify immunoglobulin G (IgG)
antibodies directed against a broad panel of S. aureus proteins
in mouse serum, and we assessed cross reactivity. In addition,
this technique was applied to analyse serum samples from
mice with different types of S. aureus infections caused by
different S. aureus strains.
2. Materials and methods
2.1. Serum samples from mice immunized with monovalent
staphylococcal vaccine candidates
Female BALB/cOlaHsd mice (6–8 weeks old, speciﬁed
pathogen free) were immunized intranasally (5 mice per
group) with monovalent Gram-positive Enhancer Matrix
(GEM)-based vaccines containing clumping factor A (ClfA),
extracellular ﬁbrinogen-binding protein (Efb), or toxic shock
syndrome toxin 1 (TSST-1). One dose of vaccine consisted of
2.5×109 GEM-particles containing 8.0, 2.0, or 2.1 μg ClfA, Efb,
or TSST-1, respectively, in a volume of 10 μL. Another group of
mice was immunized subcutaneously (4 mice per group)
with monovalent GEM-based vaccines containing endonu-
clease (Nuc), peptidoglycan hydrolase (LytM), or immuno-
dominant staphylococcal antigen A (IsaA). One dose of
vaccine consisted of 2.5×109 GEM-particles containing 25.0,
10.0, or 17.5 μg Nuc, LytM, or IsaA, respectively, in a volume of
100 μL. The immunization schedule consisted of three dosesgiven at 10-day intervals. Animal experiments were per-
formed with approval of the Animal Experimentation
Committee of the University of Groningen, The Netherlands.
Sera were collected before immunization and 2 weeks after
the last immunization.
2.2. Serum samples from mice with lung infection or skin
infection caused by S. aureus strain LAC
Sera from mice with lung infection or skin infection
caused by S. aureus strain LAC (USA300) were obtained from
Dr. M.G. Bowden and prepared as described (Brown et al.,
2009b). In short, female BALB/c mice (6 weeks old, speciﬁed
pathogen free) were inoculated intranasally (5×107 CFU in
20 μL, 9 mice) for lung infection or intradermally (1×107 CFU
in 50 μL, 10 mice) for skin infection with S. aureus strain LAC.
Sera were collected 5 weeks after infection.
2.3. Serum samples from mice with intravenously-induced
bacteraemia caused by different S. aureus strains
Female BALB/cBYJ mice (11–13 weeks old, speciﬁed
opportunistic pathogen free) were inoculated intravenously
via the tail vein with S. aureus clinical isolate P or S. aureus
clinical isolate S (7×104 CFU in 100 μL, 5 mice per group).
Animal experiments were performed with approval of the
Institutional Animal Care and Use Committee of the Erasmus
University Medical Centre Rotterdam, The Netherlands. S.
aureus clinical MSSA isolates P and S were kindly provided by
Dr. G. Buist (University Medical Centre Groningen, The
Netherlands). The characterization of these S. aureus isolates
based on proteomic analysis has been described by Ziebandt
A.K. et al. (2010). Sera were collected before and 2, 3, and
5 weeks after infection.
2.4. Proteins
The following puriﬁed proteins of S. aureus were coupled
to Sero-MAP beads: Nuc; LytM; IsaA; ClfA; clumping factor B
(ClfB); iron-responsive surface determinants A and H (IsdA
and IsdH); ﬁbronectin-binding proteins A and B (FnbpA and
FnbpB); extracellular ﬁbrinogen-binding protein (Efb);
staphylococcal complement inhibitor (SCIN); alpha toxin; γ
hemolysin B (HlgB); leukocidins D, E, F, and S (LukD, LukE,
LukF, and LukS); staphylococcal enterotoxins A–C (SEA–SEC);
toxic shock syndrome toxin 1 (TSST-1); and staphylococcal
superantigen-like proteins 1, 3, 5, 9, and 11 (SSL1, SSL3, SSL5,
SSL9, and SSL11). G. Buist (University Medical Centre
Groningen, Groningen, The Netherlands) supplied Nuc,
LytM, and IsaA (Ziebandt et al., 2010). ClfA was kindly
provided by T. Bosma (BiOMaDe Technology, Groningen, The
Netherlands). ClfB, IsdA, IsdH, FnbpA, and FnbpB were
expressed and puriﬁed as described previously (Verkaik et
al., 2009a). The constructs were provided by T. Foster (Trinity
College, Dublin, Ireland). J.I. Flock (Karolinska Institutet,
Stockholm, Sweden) supplied Efb (Shannon et al., 2005). S.
Rooijakkers (University Medical Centre Utrecht, Utrecht, The
Netherlands) provided SCIN (Rooijakkers et al., 2005). Alpha
toxin, HlgB, LukD, LukE, LukF, LukS, SEA, and SEC were
prepared as described previously (Verkaik et al., 2010b). SEB
and TSST-1 were provided by S. Holtfreter and D. Grumann
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et al., 2006). SSL1, SSL3, SSL5, SSL9, and SSL11were a gift from
J.D. Fraser (University of Auckland, Auckland, New Zealand)
(Chung et al., 2007).
The coupling procedure was performed as described
elsewhere (Martins et al., 2006; Verkaik et al., 2008, 2009a).
In short, 25 μg of proteinwas added to 5.0×106microspheres.
This amount of protein was found to be optimal. As an
activation buffer, we used 100 mmol/L monobasic sodium
phosphate (pH 6.2). To activate the carboxyl groups on the
surface of the beads, 10 μL of 50 mg/mL N-hydroxysulfosuc-
cinimide and 1-ethyl-3-(3-dimethylaminopropyl) carbodii-
mide was used (Pierce Biotechnology). The coupling buffer
consisted of 50 mmol/L 2-(N-morpholino)-ethanesulfonic
acid (pH 5.0; Sigma-Aldrich). The ﬁnal concentration of
microspheres was adjusted to 3000 beads/μL with blocking-
storage buffer (PBS–BN) consisting of phosphate-buffered
saline (PBS), 1% bovine serum albumin, and 0.05% sodium
azide (pH 7.4). The microspheres were protected from light
and stored at 4 °C until use. For control beads, the coupling
procedure was performed in the absence of S. aureus protein.
In each experiment, control beads were included to deter-
mine nonspeciﬁc binding. In case of nonspeciﬁc binding, the
median ﬂuorescence intensity (MFI) values were subtracted
from the protein-speciﬁc results. As a negative control, PBS–
BN was included.
2.5. Multiplex S. aureus antibody assay
Immunoglobulin G (IgG) levels in serum directed against
the above mentioned proteins were quantiﬁed simultaneous-
ly using a bead-based ﬂow cytometry technique (xMap;
Luminex Corporation). Methods have been described else-
where (Martins et al., 2006; Verkaik et al., 2008, 2009a). In
brief, 50 μL of serum, diluted 1/100 in PBS–BN was incubated
with the microspheres in a 96-well 1.2-μm polyvinylidene
ﬂuoride ﬁlter microtiter plate (Millipore) for 35 min at room
temperature on a Thermomixer plate shaker (Eppendorf).
The plate was washed twice with PBS–BN that was aspirated
by vacuum manifold. The microspheres (3000 beads per
colour per well) were re-suspended in 50 μL of PBS–BN. In
separate wells, 50 μL of a 1/100 dilution of R-phycoerythrin
(RPE)-conjugated AfﬁniPure goat anti-mouse IgG (Abcam)
was added. The plate was incubated for 35 min at room
temperature on the plate shaker at 800 rpm and washed. The
microspheres were re-suspended in 100 μL of PBS–BN.
Measurements were performed on the Luminex 100 instru-
ment (BMD) using Luminex IS software (version 2.3). Tests
were performed in independent duplicates, and median
ﬂuorescence intensity (MFI) values, reﬂecting semi-quanti-
tative antibody levels, were averaged. The coefﬁcient of
variation (CV) was calculated for each serum sample and
averaged per protein.
The multiplex S. aureus antibody assays (serum incubated
with the different ﬂuorescence-coloured protein-coupled
beads mixed in one well) were developed. Two multiplex
assays were used, one including Nuc, LytM, ClfA, and IsaA
(multiplex 1), the other including ClfB, IsdA, IsdH, FnbpA,
FnbpB, Efb, SCIN, alpha toxin, HlgB, LukD, LukE, LukF, LukS,
SEA, SEB, SEC, TSST-1, SSL1, SSL3, SSL5, SSL9, and SSL11
(multiplex 2). Multiplex 2 was veriﬁed in a previous study(Verkaik et al., 2010a) using human pooled serum (HPS).
Multiplex 1 was veriﬁed in the present study using HPS. HPS
was obtained from 36 healthy human donors of unknown S.
aureus nasal carriage state (Verkaik et al., 2009a). MFI values
for HPS obtained with the multiplex assay 1 were compared
with the results for HPS obtained with singleplex assays
(serum incubated with each different colour of protein-
coupled beads in separate wells). Cross reactivity between
proteins and antibodies was assessed using serum samples
from mice immunized with monovalent staphylococcal
vaccines. Serum samples from mice with lung infection or
skin infection caused by S. aureus strain LAC and from mice
with intravenously-induced bacteraemia caused by S. aureus
isolate P or isolate S were analysed. Mouse pooled serum
(MPS) was used as a positive control. For MPS, mice
inoculated intravenously with 5×105 CFU of S. aureus isolate
P were bled 5 weeks after infection. Serum from non-infected
mice was used as a negative control.
2.6. Statistical analysis
Statistical analyses were performed with SPSS software,
version 15.0 (SPSS). The Mann–Whitney U test was used to
comparemedian differences in anti-staphylococcal IgG levels.
Differences were considered statistically signiﬁcant when 2-
sided P-values were b0.05.
3. Results
3.1. Optimization and veriﬁcation of the multiplex S. aureus
antibody assay
In multiplex 1 and multiplex 2, a 1/100 dilution of mouse
serum and a 1/100 dilution of RPE-conjugated AfﬁniPure goat
anti-mouse IgG were found to be optimal. Next, multiplex 1
was veriﬁed using HPS. MFI values obtained for HPS with
multiplex 1 were 76%, 80%, 94%, and 95% for Nuc, LytM, ClfA,
and IsaA, respectively, of the MFI values obtained with the
singleplex assays, indicating that multiplex 1 was approved
for use. In multiplex 1 and multiplex 2, serum incubated with
control beads (beads without protein coupled on their
surface) resulted in median MFI values for IgG of 8 (range,
5–85), indicating that nonspeciﬁc binding was low. The
negative control (PBS–BN) incubated with protein-coupled
beads also resulted in low MFI values (≤12).
3.2. Reproducibility of the multiplex S. aureus antibody assay
For multiplex 1 and multiplex 2, inter-assay variation was
investigated and calculated from MFI values obtained for
MPS, which was included on each 96-wells plate. MFI values
were averaged per protein. The median CV was 16%, and the
range was 7% (IsaA) to 39% (LukF). The relatively high CV for
LukF was due to the low MFI values, being close to 0.
3.3. Antibody proﬁle in sera from mice immunized with
monovalent staphylococcal vaccine candidates
To assess whether proteins on the microspheres cross
reacted with serum antibodies directed against other pro-
teins, the antibody proﬁle in serum samples from mice
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vaccines was determined. The MFI values reﬂecting serum
IgG levels for individual mice are shown in Fig. 1. In serum
from protein-vaccinated mice, median serum IgG levels
directed against the vaccine protein were high, while IgG
levels against the other proteins were low.
3.4. Antibody proﬁle in sera from mice with lung infection or
skin infection caused by S. aureus strain LAC
The MFI values reﬂecting serum IgG levels for individual
mice at 5 weeks after infection are shown in Fig. 2. The
protein-speciﬁc antibody levels showed substantial inter-
individual variability. Median IgG levels in sera from non-
infected mice were low and comparable to the negative
control (PBS–BN). In both lung-infected mice and skin-
infected mice, median serum IgG levels directed against Nuc,
IsaA, Efb, alpha toxin, LukE, LukS, and SSL1 were signiﬁcantly
increased compared to non-infected mice. Interestingly,
differences between mice with lung infection or with skin
infection caused by the same strain were also observed.
Median IgG levels directed against IsdA, FnbpB, SCIN, HlgB,
LukF, TSST-1, SSL5, and SSL9 were signiﬁcantly increased only
in lung-infected mice and not in skin-infected mice.
3.5. Antibody proﬁle in sera from mice with intravenously-
induced bacteraemia caused by different S. aureus strains
The MFI values reﬂecting median IgG levels in mice before
and at various intervals after infection are shown in Fig. 3.
Differences between S. aureus isolate P-infected mice and S.Fig. 1.Median ﬂuorescence intensity (MFI) values reﬂecting levels of protein-speciﬁc
GEM-based monovalent staphylococcal vaccines. Different symbols represent mice i
light green diamonds for LytM containing vaccine, red triangles for ClfA containin
containing vaccine, and dark green plus signs for TSST-1 containing vaccine. Med
endonuclease; LytM, peptidoglycan hydrolase; Clf, clumping factor; Isa, immunodom
TSST, toxic shock syndrome toxin.aureus isolate S-infected mice were only calculated for
median IgG levels found at 5 weeks after infection. In both
groups, isolate P-infected mice and isolate S-infected mice,
one out of ﬁve mice died. Although protein-speciﬁc median
IgG levels for SEA and TSST-1 were low, the median IgG levels
were signiﬁcantly increased in isolate S-infected mice
compared to isolate P-infected mice. For Nuc, IsdA, Efb,
SSL1, and SSL5 median IgG levels were signiﬁcantly increased
in isolate S-infected mice compared to isolate P-infected
mice. Median IgG levels directed against most S. aureus
proteins (for example Efb, HlgB, LukD, and LukF) increased
with progression of bacteraemia up to a maximum at 5 weeks
after infection, whereas towards some S. aureus proteins the
maximum IgG levels were found at 2 or 3 weeks after
infection (for example SCIN, alpha toxin, and SSL1).
4. Discussion
Themultiplex S. aureus antibody assay is a suitable tool for
investigating the humoral immune response against S. aureus
proteins andmay provide further insight into the role of these
antigens in nasal colonization and infections with S. aureus in
humans (Verkaik et al., 2009a, 2010a,b). With this assay
antibodies directed to at least 26 proteins can be measured in
small volumes of serum, which in this respect is an advantage
over the conventional ELISA technique. In the present study,
we adapted this multiplex S. aureus antibody assay for use in
experimental S. aureus infections in mice. The assay was
optimized and veriﬁed for measuring IgG levels in mouse
serum. For this purpose, sera from mice immunized with
GEM-based monovalent staphylococcal vaccines were used.IgG for six Staphylococcus aureus proteins in sera frommice immunized with
mmunized with different vaccines: black squares for Nuc containing vaccine,
g vaccine, turquoise crosses for IsaA containing vaccine, blue circles for Efb
ian levels of anti-staphylococcal IgG are indicated by horizontal lines. Nuc,
inant staphylococcal antigen; Efb, extracellular ﬁbrinogen-binding protein;
Fig. 2. Median ﬂuorescence intensity (MFI) values reﬂecting levels of protein-speciﬁc IgG for 26 Staphylococcus aureus proteins in sera from mice 5 weeks after
induction of lung infection or skin infection caused by S. aureus strain LAC. Different symbols representmicewith different infections: red squares formicewith lung
infection, green diamonds for mice with skin infection, and turquoise triangles for non-infected mice. Median levels of anti-staphylococcal IgG are indicated by
horizontal lines. Statistically signiﬁcant differences inmedian values are indicated betweenmicewith lung infection and non-infectedmice (&), betweenmicewith
skin infection and non-infectedmice ($), and betweenmicewith lung infection andmicewith skin infection (#). Differences in protein-speciﬁcMFI values between
groups were considered to be statistically signiﬁcant at Pb0.05 (Mann–Whitney U test). Nuc, endonuclease; LytM, peptidoglycan hydrolase; Isa, immunodominant
staphylococcal antigen; Clf, clumping factor; Isd, iron-responsive surface determinant; Fnbp, ﬁbronectin-binding protein; Efb, extracellular ﬁbrinogen-binding
protein; SCIN, staphylococcal complement inhibitor; Hlg, γ hemolysin; Luk, leukocidin; SE, staphylococcal enterotoxin; TSST, toxic shock syndrome toxin; SSL,
staphylococcal superantigen-like protein.
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Audouy S.A.L. et al. as an efﬁcient delivery system for mucosal
vaccination (Audouy et al., 2006, 2007). We showed thatFig. 3. Median ﬂuorescence intensity (MFI) values reﬂecting levels of protein-spe
intervals after induction of intravenously-induced bacteraemia caused by different S
2 weeks, 3 weeks, and 5 weeks after infection, respectively. Statistically signiﬁcant d
caused by S. aureus isolate P and mice with bacteraemia caused by S. aureus isolate S
values between groups were considered to be statistically signiﬁcant at Pb0.05 (Ma
immunodominant staphylococcal antigen; Clf, clumping factor; Isd, iron-responsiv
ﬁbrinogen-binding protein; SCIN, staphylococcal complement inhibitor; Hlg, γ he
syndrome toxin; SSL, staphylococcal superantigen-like protein.cross reactivity between proteins onmicrospheres and serum
antibodies towards other proteins was limited. It was
concluded that the multiplex S. aureus antibody assay canciﬁc IgG for 26 Staphylococcus aureus proteins in sera from mice at various
. aureus strains. Bars from left to right reﬂect IgG levels before infection, and a
ifferences in median IgG values are indicated between mice with bacteraemia
at 5 weeks after bacterial inoculation (*). Differences in protein-speciﬁc MF
nn–Whitney U test). Nuc, endonuclease; LytM, peptidoglycan hydrolase; Isa
e surface determinant; Fnbp, ﬁbronectin-binding protein; Efb, extracellular
molysin; Luk, leukocidin; SE, staphylococcal enterotoxin; TSST, toxic shockt
I
,
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speciﬁc for S. aureus proteins.
In the present study, themultiplex S. aureus antibody assay
was used to characterize the IgG proﬁle in sera frommicewith
lung infection or skin infection caused by the same S. aureus
strain LAC. Our data showed that the site of infection
inﬂuences the IgG proﬁle. Mice with severe lung infection
had a higher and broader IgG response compared tomicewith
skin infection. Differences were most striking for the sortase-
anchored surface protein IsdA, the immune modulators Efb
andSCIN, themembers of the leukotoxin familyHlgB andLukF,
and superantigen-likeproteins SSL5, 9, and11. BrownE.L. et al.
(2009b) already described the characteristics of these mice
infected with severe lung infection or skin infection caused by
S. aureus strain LAC, in terms of the course of infection,
histopathology and quantitative cultures from the infected
tissue. Mice in both infection groups survived the infection. In
their study, the antibody reactivity to a panel of S. aureus
proteins was measured 4 weeks after skin infection with S.
aureus strain LAC. Thesemice developed a signiﬁcant response
to LukF, LukS, alpha toxin, and Efb.We also observed increased
IgG levels against LukS and alpha toxin at 5 weeks after skin
infection. However IgG levels for LukF and Efb were low.
Next, the multiplex S. aureus antibody assay was applied
to characterize the IgG proﬁle in sera from mice with similar
infections, intravenously-induced bacteraemia, caused by
different S. aureus strains, isolate P or isolate S. These studies
revealed different IgG responses against both S. aureus
isolates. This observation in mice correlates well with data
obtained in patients with S. aureus bacteraemia, in whom
antibody responses during the course of infection were
speciﬁc for each patient (Verkaik et al., 2010a). In mice with
bacteraemia caused by S. aureus isolate S we observed a
broader IgG response compared to mice with bacteraemia
caused by S. aureus isolate P, indicating that each S. aureus
strain, exhibiting its own speciﬁc protein expression during
infection, generates a characteristic IgG antibody proﬁle over
time. Most striking were the IgG levels for the sortase-
anchored surface protein IsdA, the immune modulator Efb,
superantigen-like proteins SSL1 and 5, and the nuclease Nuc,
being signiﬁcantly increased in isolate S-infected mice
compared to isolate P-infected mice.
Summarizing, the data from the present study show that a
bead-based multiplex S. aureus antibody assay can be
successfully applied for investigating IgG responses related
to S. aureus infections in mice. Only a small serum volume in
the order of one to a few microlitres is required. With this
technique the immunogenicity of different proteins during
the course of different S. aureus infections can be determined
in mice. When measuring antibody levels in sera from
patients, it is hard to assess the humoral immune response
towards the causative S. aureus strain in infection, as patients
probably had some or more previous encounters with
different S. aureus strains. The use of S. aureus-free mice,
which never have had contact with S. aureus before induction
of the experimental infection, enables to assess and quantify
the primary antibody responses to speciﬁc S. aureus proteins,
and to investigate whether the immunogenicity of S. aureus
proteins depended on the site of infection and/or the S. aureus
isolate causing the infection. Whereas our study was focused
exclusively on IgG directed against S. aureus proteins, itshould be noted that cell-wall components, such as capsular
polysaccharides 5 and 8 (Fattom et al., 2004), peptidoglycan
(Verbrugh et al., 1981) and lipoteichoic acid (Wergeland et
al., 1984), are also known to be immunogenic. In future
studies we will include the analysis of the host response
against these cell-wall components as well. Moreover, next to
IgG levels, other immunoglobulins and their subclasses will
be investigated.
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